Healthcare -
Biotechnology - NASDAQ - IL
$ 3.02
-4.42 %
$ 256 M
Market Cap
-6.11
P/E
1. INTRINSIC VALUE
Balance Sheet
Alpha Tau Medical Ltd.
| Current Assets | 64.2 M |
| Cash & Short-Term Investments | 59.6 M |
| Receivables | 332 K |
| Other Current Assets | 4.3 M |
| Non-Current Assets | 22 M |
| Long-Term Investments | 0 |
| PP&E | 21.5 M |
| Other Non-Current Assets | 432 K |
| Current Liabilities | 8.68 M |
| Accounts Payable | 3.53 M |
| Short-Term Debt | 1.01 M |
| Other Current Liabilities | 4.13 M |
| Non-Current Liabilities | 14.9 M |
| Long-Term Debt | 11.5 M |
| Other Non-Current Liabilities | 3.34 M |
EFFICIENCY
Earnings Waterfall
Alpha Tau Medical Ltd.
| Revenue | 0 |
| Cost Of Revenue | 1.1 M |
| Gross Profit | -1.1 M |
| Operating Expenses | 34.9 M |
| Operating Income | -36 M |
| Other Expenses | -4.29 M |
| Net Income | -31.8 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Alpha Tau Medical Ltd.
| Net Income | -31.8 M |
| Depreciation & Amortization | 1.1 M |
| Capital Expenditures | -2.24 M |
| Stock-Based Compensation | 9.92 M |
| Change in Working Capital | 1.17 M |
| Others | -16 K |
| Free Cash Flow | -22 M |
Wall Street Analysts Price Targets
Alpha Tau Medical Ltd.
DRTS has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
DRTS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Alpha Tau Medical Ltd.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update
- Interim Jan-2025 results from three trials of Alpha DaRT ® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate , impressive overall survival in sub-group analys e s, and positive safety profile -
globenewswire.com
- 4 weeks ago
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS , DRTSW ) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, and Chairman of the Board of Oramed Pharmaceuticals Inc., (“Oramed”), has been appointed to the Company's Board of Directors (“Board”). The appointment follows the recent closing of a strategic investment between the Company and an affiliate of Oramed.
globenewswire.com
- 1 month ago
Alpha Tau to Participate in May Investor Conferences
JERUSALEM, May 06, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will presentation in the following investor conferences in May 2025.
globenewswire.com
- 1 month ago
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that it has successfully closed a registered direct offering (the “offering”) whereby an affiliate of Oramed Pharmaceuticals Inc. (“Oramed”) (Nasdaq: ORMP) (TASE: ORMP) purchased 14,110,121 of Alpha Tau's ordinary shares, no par value, at a purchase price of $2.612 per ordinary share.
globenewswire.com
- 1 month ago
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials across four indications, manufacturing scale-up, and commercialization efforts Partnership unites two innovative therapeutic delivery pioneers – Oramed's oral drug delivery platform with Alpha Tau's precision radiation delivery technology NEW YORK , April 28, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company"), (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, announced today that it has successfully closed a strategic investment in Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®.
prnewswire.com
- 1 month ago
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with recurrent glioblastoma (GBM) using the Alpha DaRT technology.
globenewswire.com
- 2 months ago
Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update
- Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile -
globenewswire.com
- 3 months ago
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the achievement of Medical Device Single Audit Program (MDSAP) certification for the company's manufacturing facility in Jerusalem, as part of the Company's commitment to quality, safety, and regulatory compliance while accelerating the global expansion of alpha-radiation cancer therapy through the manufacturing of the Alpha DaRT.
globenewswire.com
- 3 months ago
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
- High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of Alpha DaRT ® -
globenewswire.com
- 4 months ago
Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
JERUSALEM, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that an abstract entitled “Interim analysis of feasibility, safety, and tumor control in two first-in-human trials of a novel alpha-emitting radionuclide for pancreatic adenocarcinoma,” submitted by principal investigators involved in the Company's Israeli pancreatic cancer trial, has been accepted to the 2025 ASCO Gastrointestinal Cancers Symposium, to be held January 23 – 25, 2025 in San Francisco, CA. The poster will be presented during “Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract,” on January 24, 2025 at 11:30am – 1:00pm PT.
globenewswire.com
- 5 months ago
Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
JERUSALEM, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS , DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that following its Annual General Meeting of Company shareholders in Jerusalem, Ms. Maya Netser has been appointed to the Company's Board of Directors (“Board”). Mr. Meir Jakobsohn is completing his term on the Board, having decided not to pursue re-election, but will continue to serve the Company in an advisory capacity.
globenewswire.com
- 5 months ago
Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference
The overview presentation will review some of the Company's recent achievements as well as the outlook for upcoming data milestones The overview presentation will review some of the Company's recent achievements as well as the outlook for upcoming data milestones
globenewswire.com
- 6 months ago
8. Profile
Summary
Alpha Tau Medical Ltd. DRTS
COUNTRY
IL
INDUSTRY
Biotechnology
MARKET CAP
$ 256 M
Dividend Yield
0.00%
Description
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Contact
5 Kiryat Hamada Street, Jerusalem, 9777605
https://www.alphatau.com
IPO
Date
March 8, 2021
Employees
125
Officers
Mr. Peter M. Melnyk
Chief Commercial Officer
Mr. Raphi Levy
Chief Financial Officer
Mr. Amnon Gat
Chief Operations Officer
Mr. Ronen Segal
Chief Technology Officer
Dr. Robert B. Den M.D.
Chief Medical Officer & Member of Scientific Advisory Board
Prof. Yona Keisari
Chief Scientific Officer & Member of Scientific Advisory board
Ms. Yael Zeiger
Corporate Controller
Ms. Rebecca Becker
Vice President of legal
Prof. Itzhak Kelson
Chief Physics Officer & Member of Scientific Advisory Board
Mr. Uzi Sofer
Chief Executive Officer & Chairman